Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

QUANTEL Medical Signs Global Licensing Agreement with IRIDEX



         QUANTEL Medical Signs Global Licensing Agreement with IRIDEX

IRIDEX' patented MicroPulse™ laser technology enables Fovea-friendly™ therapy
for sight-threatening eye diseases

PR Newswire

CHICAGO, November 9, 2012

CHICAGO, November 9, 2012 /PRNewswire/ --

QUANTEL Medical today announced that IRIDEX and QUANTEL Medical have signed a
global patent licensing agreement that gives QUANTEL access to IRIDEX
MicroPulse technology. This proprietary technology provides ophthalmologists a
noninvasive treatment for sight-threatening diseases of the eye, including
complications associated with diabetes. Unlike conventional laser therapy,
MicroPulse spares the eye tissue responsible for vision while producing
comparable clinical effect to traditional methods that destroy tissue.

"There is a significant need in the market place for efficient and durable
therapies for retinal diseases associated with the growth of diabetes and the
aging population," stated Will Moore, IRIDEX President and CEO.  He continued,
"With 10-year follow up data, a growing global user base, and significant
patent protection, MicroPulse is emerging as a future standard of care." The
license agreement will allow QUANTEL to market and display IRIDEX' MicroPulse
technology for their range of high quality clinical lasers and is the next
step in gaining broad market availability of MicroPulse photocoagulation
lasers. Both QUANTEL and IRIDEX offer a full line of laser systems that offer
standard photocoagulation in addition to MicroPulse laser therapy.

Moore continued, "Further establishing the MicroPulse brand and technology as
an IRIDEX  property is critical as the market continues to recognize its broad
applicability for retina and other procedures.  We look forward to working
with others in the industry as it migrates toward a new standard for laser
therapy in additional segments."  

"The global clinical evidence supporting IRIDEX' MicroPulse laser technology
was an important factor in this decision", stated Mr. Jean-Marc Gendre, CEO of
QUANTEL Medical.  He continued, "By aligning our market strategies with
another industry leader, we believe the ophthalmic community will have greater
access to MicroPulse technology, helping to improve the standard of care for
retinal diseases. We also believe that this collaboration will be the most
efficient method to standardize MicroPulse clinical protocols for our
customers."

About MicroPulse Technology

MicroPulse is a Fovea-friendly tissue-sparing laser delivery therapy that
works by electronically "chopping" the laser emission into trains of
microsecond pulses. This enhances the physician's ability to more precisely
control the laser effects on target tissues, offering the potential for ocular
treatment with less collateral effects than conventional laser treatments.  

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in
developing, manufacturing, and marketing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation for the
ophthalmology market. We maintain a deep commitment to the success of our
customers, with comprehensive technical, clinical, and service support
programs. IRIDEX is dedicated to a standard of excellence, offering superior
technology for superior results. IRIDEX products are sold in the United States
through a direct sales force and internationally through a combination of a
direct sales force and a network of approximately 70 independent distributors
into over 100 countries. For further information, visit the IRIDEX' website at
http://www.iridex.com/.

About QUANTEL Medical

Founded in 1993 and headquartered in Clermont-Ferrand, France, QUANTEL Medical
is a global ophthalmic medical device company dedicated to developing leading
technologies to improve the treatment of ocular diseases. QUANTEL Medical has
a strong emphasis in research and development, resulting in many
first-to-market product introductions, and a comprehensive product portfolio
of diagnostic ultrasound and surgical lasers for ophthalmologists. The
products are available through direct sales operations in the U.S. and France,
and through independent distributors in over 80 countries.

QUANTEL Medical is a division of Quantel (QUA:EN), a world-wide leader in the
development of solid-state lasers for scientific and industrial applications.

http://www.quantel-medical.com

CONTACT: Levi Hall, Marketing Director, Medical, Quantel USA,
lhall@quantelusa.com, +1-916-704-5384.

SOURCE QUANTEL Medical
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement